Clinical TrialsThe current dataset is small and with limited follow-up, leaving some uncertainty about the durability and response factors of SENTI-202.
Financial PositionThe company ended the quarter with a limited cash position of $10.5 million, which has decreased from the previous quarter.
Treatment EfficacyThere is a lack of clarity about why one patient did not respond to the treatment, particularly given the presence of TP53-mutated AML, which is difficult to treat.